Original Research Article

Field changes on automated Humphrey’s field analyzer in tuberculosis following ethambutol therapy

Poorva Shrivastava 1,*, Sheetal Morskole1, Lalit Shrivastava2

1 Dept. of Ophthalmology, Gandhi Medical College, Bhopal, Madhya Pradesh, India
2 Kamla Nehru Government Hospital, Bhopal, Madhya Pradesh, India

A R T I C L E  I N F O

Article history:
Received 20-06-2021
Accepted 20-07-2021
Available online 03-01-2022

Keywords:
ATT
Ethambutol
Visual field
Visual acuity
Color vision
Reversible

A B S T R A C T

Background: This study was conducted to evaluate the visual field changes in tubercular patients on anti-tubercular therapy and to assess the reversibility of these changes after the discontinuation therapy.

Materials and Methods: This study was conducted as a prospective analytical study at tertiary care centres in Bhopal and Jabalpur on all newly detected tuberculosis patients. Ocular history, relevant history was recorded and detailed ocular examination was done at the time of presentation, before initiating ATT. All the patients were followed up periodically till the cessation of treatment and three months thereafter.

Results: A total of 40 cases of newly diagnosed tuberculosis were registered with mean age of 38.4 ± 3.99 years. We documented significant deterioration in visual acuity after 3 months of initiation of therapy. Once the ATT was stopped, the improvement in visual acuity was statistically significant 3 months after the cessation of ATT as compared to visual acuity 3 months after initiation of ATT (p<0.05). But residual visual impairment even after stoppage of ATT was observed. Color vision and visual field defects were observed in higher proportions of eyes following initiation of ethambutol which improved significantly after 3 months of cessation of ATT (p<0.05).

Conclusion: Ethambutol, even in recommended dose according to DOTS, has been associated with ocular toxicity which manifests in the form of painless progressive loss of vision, color vision defects and visual field defects. Though these changes are usually reversible, few patients have irreversible damage. Thus, patients receiving ethambutol must be explained regarding these effects and followed up periodically.

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Tuberculosis, though the oldest known infectious disease, remains the leading cause of death worldwide from a single infectious agent. 1 Though, the infection can be observed all over the World, majority of cases are documented from low-middle income countries. 2 India contributes to one fifth of the global burden of tuberculosis. 3 Primarily, it is a pulmonary disease, but it can manifest as extra-pulmonary TB and may affect any organ other than lungs (e.g., pleura, lymph nodes, abdomen, genitourinary tract, skin, joints and bones, or meninges. 4 To combat this problem, Directly Observed treatment Short course (DOTS) is given under the umbrella of revised National Tuberculosis Control Program (RNTCP) throughout the country. The program caters different regimen, for different durations based upon the category of tuberculosis. 3 Isoniazid, Rifampicin, Pyrazinamide, and ethambutol are first line antitubercular drugs. 5 Ethambutol has been associated with visual side effects, especially dose dependent optic neuropathy. Ethambutol induced optic neuropathy is characterized clinically by loss of central vision, which is usually painless and progressive. Patient
may also perceive decreased color perception, especially of red green color, which is usually an early feature.\textsuperscript{6, 7} Visual field defects including the centrocaecal scotoma are commonly observed in these patients, however, temporal defects as well as constrictions of peripheral field can also be observed in these patients.\textsuperscript{8–10}

The ethambutol induced optic neuropathy is usually reversible after the drug is stopped,\textsuperscript{11} however, few studies report non reversible effects and permanent optic neuropathy.\textsuperscript{12, 13} With the above background, this study was conducted to evaluate the visual field changes in tubercular patients on anti-tubercular therapy and to assess the reversibility of these changes after the discontinuation therapy. The primary objective of the study was to analyse visual field changes following initiation of ATT and to assess the regression of visual filed changes and improvement of visual acuity after stopping ATT.

2. Materials and Methods

The present study was conducted as a prospective analytical study at DOTS centre in collaboration with Department of Ophthalmology, Netaji Subhash Chandra Bose Govt medical college, Jabalpur and Kamla Nehru Hospital, Bhopal, during the study period of 2 years i.e. from 16th January 2018 to 15th January 2020. All the patients diagnosed as “new case” of tuberculosis (pulmonary or extra-pulmonary), belonging to age range of 18 to 70 years of either gender, reporting at the study area during the study period and willing to participate in the study were included. Patients who were on anti-tubercular therapy (dosage of ethambutol – 15 mg/kg PO qDay) already, with history of tubercular meningitis, renal diseases, past history of anti-tubercular therapy, history of vasculitis, demyelinating diseases, other infectious causes of optic neuritis and optic disc edema were excluded.

After obtaining ethical clearance from the institute’s ethical committee, all the patients fulfilling inclusion criteria and giving consent were included. Detailed history regarding sociodemographic variables were obtained and entered in the proforma. Ocular history, relevant medical, surgical and family history was recorded from the patients. Ocular examination was done in detail which included best corrected visual acuity, color vision testing by Ishihara’s pseudo chromatic color blindness chart, contrast sensitivity, intraocular tension assessment, slit lamp bio-microscopic examination, fundus examination and visual field analysis by automated Humphrey visual field analyzer (Appasamy auto perimeter; model: glaufield lite: AP-901252) was done at the time of presentation, before initiating ATT.

All the patients were followed up periodically till the cessation of treatment and three months thereafter. Ocular examination including color perception, visual acuity and changes in the visual fields were done at the end of three months of therapy and after cessation of three months of therapy.

Statistical analysis- Data was entered in MsExcel and IBM SPSS software version 20 was used for data analysis. Chi square test was used to assess the ocular changes during various follow up. P value less than 0.05 was considered statistically significant.

3. Results

A total of 40 cases of newly diagnosed tuberculosis were registered with mean age of 38.4±13.99 years.

Majority of patients with tuberculosis belonged to 31 to 40 years of age (27.5%). Males were predominantly affected (70%) as compared to females (30%). About 57.5% cases presented with pulmonary tuberculosis and duration of therapy in majority of cases was 9 months with mean duration of 11.3±4.2 months.

A total of 80 eyes of 40 patients were further analyzed in our study.

Majority of eyes had visual acuity of 6/6 (61.3%) at the time of presentation. However, we documented significant deterioration in visual acuity after 3 months of initiation of therapy. Once the ATT was stopped, the improvement in visual acuity was statistically significant 3 months after the cessation of ATT as compared to visual acuity 3 months after initiation of ATT (p<0.05). But visual acuity 3 months after the cessation of ATT was significantly worse as compared to baseline visual acuity (p<0.05), indicating residual visual impairment even after stoppage of ATT.

In present study, normal color vision was noted in all the eyes, whereas at the end of 3 months of initiation of ATT, 15% eyes had defective color vision, most common being blue yellow defect (5%). Thereafter, color vision improved significantly after 3 months of cessation of ATT (p<0.05).

Among 80 eyes screened at the time of presentation, none of the eyes had visual field defects, whereas during the course of ATT, 25% eyes had visual field defects and most common visual field defects were central scotoma (11.3%). However, visual field defects were reversible in only 5 eyes after cessation of ATT i.e. reversible ethambutol induced optic neuritis was observed in 2 (2.5%) eyes with central scotoma, 1 (1.25%) eye with peripheral constriction and 3(3.75%) eyes with peripheral defects. The observed improvement was statistically significant three months after the cessation of ATT (p<0.05).

4. Discussions

Tuberculosis is still one of the major cause of morbidity as well as mortality especially in low middle income countries. Though anti-tuberculergic drugs are effective in management of tuberculosis, they are associated with several side effects. Ethambutol, a first line bacteriostatic anti-tubercular drug has been associated with toxic optic neuropathy in a dose dependent manner.\textsuperscript{14, 15} The exact mechanism of ethambutol
**Table 1:** Distribution of patients according to baseline variables

| Variables                | Frequency (n=40) | Percentage |
|--------------------------|------------------|------------|
| **Age (years)**          |                  |            |
| ≤20                      | 4                | 10.0       |
| 21-30                    | 10               | 25.0       |
| 31-40                    | 11               | 27.5       |
| 41-50                    | 7                | 17.5       |
| >50                      | 8                | 20.0       |
| **Gender**               |                  |            |
| Male                     | 28               | 70.0       |
| Female                   | 12               | 30.0       |
| **Site of tuberculosis** |                  |            |
| Pulmonary                | 23               | 57.5       |
| Extra-pulmonary          | 17               | 42.5       |
| **Duration of ATT**      |                  |            |
| 6 months                 | 5                | 12.5       |
| 9 months                 | 20               | 50.0       |
| 12 months                | 5                | 12.5       |
| 18 months                | 10               | 25.0       |

**Table 2:** Visual acuity at various follow up

| Visual acuity | At presentation | 3 months after initiating ATT | 3 months after cessation of ATT |
|---------------|-----------------|------------------------------|--------------------------------|
|               | N     | %    | n      | %    | n      | %    |
| 6/6           | 49    | 61.3 | 40     | 50.0 | 44     | 55.0 |
| 6/9-6/12      | 23    | 28.7 | 29     | 36.25| 28     | 35.0 |
| 6/18-6/24     | 8     | 10.0 | 9      | 11.25| 7      | 8.75 |
| 6/36-6/60     | 0     | 0    | 2      | 2.5  | 1      | 1.25 |

P value 0.001

**Table 3:** Color vision at various follow ups

| Color vision         | At presentation | 3 months after initiating ATT | 3 months after cessation of ATT |
|----------------------|-----------------|------------------------------|--------------------------------|
|                      | N    | %    | N      | %    | n      | %    |
| Blue defect          | 0    | 0    | 3      | 3.8  | 1      | 1.25 |
| Blue yellow defect   | 0    | 0    | 4      | 5.0  | 2      | 2.5  |
| Red defect           | 0    | 0    | 2      | 2.5  | 1      | 1.25 |
| Red green defect     | 0    | 0    | 3      | 3.8  | 2      | 2.5  |
| Normal               | 80   | 100.0| 68     | 85.0 | 74     | 92.5 |

P value 0.001

**Table 4:** Visual field changes at various follow up

| Visual field                      | At presentation | 3 months after initiating ATT | 3 months after cessation of ATT |
|-----------------------------------|-----------------|------------------------------|--------------------------------|
|                                   | N    | %    | N      | %    | N      | %    |
| Central scotoma                   | 0    | 0    | 9      | 11.3 | 7      | 8.8  |
| Peripheral constriction           | 0    | 0    | 5      | 6.3  | 4      | 7.5  |
| Peripheral defects in different quadrants | 0    | 0    | 6      | 7.5  | 3      | 3.8  |
| None                              | 80   | 100.0| 60     | 75.0 | 66     | 82.5 |

P value 0.001
induced optic neuropathy remains unknown, however, it has been documented that EMB is a metal chelator, and has structural similarity with human mitochondrial DNA. When administered, the drug inhibits arabinosyl transferase, and prevents cell wall synthesis in mycobacteria. Apart from this, bacterial ribosomes allow the drug to disturb human mitochondria. It has been postulated that it promotes apoptosis of retinal ganglionic cells via two mechanisms i.e. decreased levels of copper in mitochondria or accumulation of zinc in lysosomes of retinal ganglion cells.\textsuperscript{16,17} Particularly, retinal ganglion cells located at papillomacular bundle is susceptible to damage, but ethambutol induced dysfunction of lysosome may lead to non-specific changes in all retinal ganglionic cells.\textsuperscript{16,17} In our study, visual acuity ranged from 6/6 to 6/24 at baseline, which decreased significantly following initiation of ethambutol. Though visual acuity improved significantly after the cessation of ethambutol but visual acuity even after cessation of ethambutol was significantly poor as compared to that of baseline. Thus, ethambutol may lead to permanent damage and have some residual effect even after its cessation. This has been attributed to ethambutol induced action on retinal ganglionic cells and visual field changes, which may be reversible or irreversible.\textsuperscript{11–13} Our study findings were concordant to findings of Mahrukh et al. in which authors documented significantly poor visual acuity after 2 months of ethambutol which improved significantly two months after cessation of ethambutol.\textsuperscript{5} However, our findings were contrasting to findings of Menon et al. and Kim et al in which they observed no change in visual acuity following ethambutol therapy.\textsuperscript{18,19} However, ethambutol induced optic neuropathy is typically associated with bilateral, progressive, and painless loss of visual acuity.\textsuperscript{11} Though many reports suggest that ethambutol is associated with reversible toxicity, but permanent visual loss has also been documented.\textsuperscript{20} Inocencio et al documented significantly higher proportion of permanent visual loss in 79.4% cases.\textsuperscript{21} Thus, visual screening of all patients on ethambutol therapy is necessary to detect early toxicity and prevention of visual impairment.

Decreased color vision and contrast sensitivity is one of the early feature of ethambutol induced optic neuropathy. Though, the typical type of color vision abnormality followed by ethambutol is not clearly known, acquired color vision defects have been categorized as blue yellow and red green defect. Acquired red-green defects are similar to inherited color defects whereas blue-yellow defects are perceived as acquired.\textsuperscript{20} In our study, Blue yellow defect was the most common defect in color vision following ethambutol. Color vision restored to normal in significant proportions of patients after the cessation of ethambutol therapy (p<0.05). Similarly, Cruz et al documented restoration of color vision to normal in 83.3% patients after discontinuation of ethambutol therapy.\textsuperscript{20} Sjoerdsma et al postulated that ethambutol shift the threshold for chromatic discrimination but does not alter the absolute sensitivity of the cone system in goldfish.\textsuperscript{22} However, Van Dijk et al\textsuperscript{23} and Kohler et al\textsuperscript{24} hypothesized that ethambutol affects the inner plexiform layer of retina and most common retinal cells affected due to ethambutol toxicity are bipolar cells, amacrine cells, and horizontal cells. Our study findings were supported by findings of Polak et al, in which the authors documented blue-yellow color-vision changes as one of the earliest feature of ethambutol induced toxicity.\textsuperscript{25} However, Kaimbo et al documented red-green and blue-yellow combined (13.1%) followed by blue-yellow defect (7.5 %) as the most common color defect in patients receiving ethambutol.\textsuperscript{26}
Assessment of visual field is one of the important screening tool for evaluation of lesions involving visual pathways. In our study, visual field defects were assessed using Automated Humphrey’s Field Analyzer. None of the patients had visual field defects at the time of presentation in any eye. However, ethambutol was associated with significant visual field defects (25%), most common being central scotoma (11.3%). These defects reversed after cessation of therapy in 5 eyes i.e. 2 eyes with central scotoma and 3 eyes with peripheral defects. Peripheral constrictions were also observed in few patients but the changes were irreversible. Similar to present study, previous studies have reported bilateral and relatively symmetrical or caecocentral visual field defects following ethambutol therapy.\(^3\)\(^,\)\(^27\) Mahrul\(k\) et al\(^5\) also documented significant visual field defects following ethambutol therapy but in contrast to present study, they documented peripheral defects in different quadrants as most common defects. Similar to our study, they also observed significant improvement in visual fields two months after the cessation of ethambutol.\(^5\) Kho et al demonstrated worst visual field in temporal hemi fields with some degree of degree of margination with superimposed central/centrocaecalscotomas in majority of eyes. Also they documented visual field improvement in 79% eyes within 15.7 months of discontinuing ethambutol.\(^27\) Menon et al documented visual field defects in 7.6% eyes during ethambutol therapy which reversed in 80% cases after stopping ethambutol.\(^18\) Garg et al however observed significant improvement of visual field defect after discontinuation of ethambutol.\(^28\)

The present study had certain limitations. Though the duration of ATT was considered, mean duration of occurrence of visual impairment could not be observed as patients were followed up only twice i.e. after 3 months of initiation of ATT and after 3 months of stopping ATT. Secondly, risk factors associated with visual field defects and their reversibility could not be assessed.

5. Conclusion
Ethambutol, even in recommended dose according to DOTS, has been associated with ocular toxicity which manifest in the form of painless progressive loss of vision, color vision defects and visual field defects. Though these changes are usually reversible, few patients have irreversible damage. Thus, patients receiving first line anti-tubercular drug, especially ethambutol, must be explained regarding these effects and followed up periodically so that ethambutol induced optic toxicity could be identified early and appropriate intervention can be applied to prevent irreversible damage.

6. Source of Funding
None.

7. Conflict of Interest
None.

References
1. Langer AJ, Iqbal SA, Pratt R. Tuberculosis statistics in United States. Report, United States Department of Health and Human Services, Public Health Services, Centres for Disease Control, Atlanta, GA, 1989, 1991.
2. Varma D, Anand S, Reddy AR, Das A, Watson JP, Currie DC, et al. Tuberculosis: an under-diagnosed aetiological agent in uveitis with an effective treatment. Eye. 2006;20(9):1068–73.
3. Garg P, Garg R, Prasad R, Mishra AK. A prospective study of ocular toxicity in patients receiving ethambutol as a part of directly observed treatment strategy therapy. Lung India. 2015;32(1):16–9.
4. Komapanapalli SK, Prasad U, Atla B, Vasundhara N, Yendului D. Role of CB-NAAT in diagnosing extra pulmonary tuberculosis in correlation with FNA in a tertiary care center. Int J Res Med Sci. 2018;6(12):4039–45.
5. Manikeshk AA, Bhat MA. Visual field changes in patients receiving anti-tubercular drug therapy at tertiary care hospital: an analytical observational study. Int J Contemp Med Res. 2017;4(2):346–9.
6. Chen L, Liang Y. Optic nerve neuropathy by ethambutol toxicity. Chinese J Tuberc Respir Dis. 1999;22(5):302–4.
7. Lucho VJ, Busto RD, Odel J. Isoniazid and Ethambutol as a cause of optic neuropathy. Eur J Resp Dis. 1987;71(1):42–5.
8. Trustwied C. Farnsworth 100-hue test in diagnosis of ethambutol induced damage to optic nerve. Ophthalmologica. 1975;171(6):425–31.
9. Lai BB, Gupta RL. Visual pattern in ethambutol treated tubercular patients. Indian J Tub. 1980;XXXIX(4).
10. Fang JT, Chen YC, Chang MY. Ethambutol induced optic neuritis in patients with end stage renal disease on hemodialysis. Ren Fail. 2004;26:189–93.
11. Carr RE, Henkind P. Ocular manifestations of ethambutol, toxic amblyopia after administration of an experimental antituberculous drug. Arch Ophthalmol. 1962;67:566–71.
12. Woman LC, Jou JR, Liaw SL. Visual function in recovered ethambutol optic neuropathy. J Ocul Pharmacol Ther. 1995;11(3):411–9.
13. Tsai RK, Lee YH. Reversibility of ethambutol optic neuropathy. J Ocul Pharmacol Ther. 1997;13(5):473–7.
14. Leibold JE. The ocular toxicity of ethambutol and its relation to dose. Ann NY Acad Sci. 1966;135(2):904–9.
15. Citron KM. Ethambutol: a review with special reference to ocular toxicity. Tubercle. 1969;50:32–6.
16. Kozak SF, Inderlied CB, Hsu HY, Heller KB, Sadun AA. The role of copper on ethambutol’s antimicrobial action and implications for ethambutol-induced optic neuropathy. Diagn Microbiol Infect Dis. 1998;30(2):83–7.
17. Chung H, Yoon YH, Hwang JJ, Cho KS, Koh JY, Kim JG. Ethambutol-induced toxicity is mediated by zinc and lysosomal membrane permeabilization in cultured retinal cells. Toxicol Appl Pharmacol. 2009;235(2):163–70.
18. Menon V, Jain D, Saxena R, Sood R. Prospective evaluation of visual function for early detection of ethambutol toxicity. Br J Ophthmol. 2009;93(9):1251–4.
19. Kim KL, Park SP. Visual function test for early detection of ethambutol induced ocular toxicity at the subclinical level. Catan Ocul Toxicol. 2016;35(3):228–32.
20. Cruz EM, Puentespina FG, Alejo KP, Santos-Morabe ET, Nañagas ML. Color-vision abnormalities among patients undergoing tuberculosis treatment. Philipp J Ophthmol. 2010;35(1):3–9.
21. Inocencio FP. Toxic optic neuropathy secondary to ethambutol. Phil J Ophthmol. 1999;24:65–8.
22. Sjoerdtsma T, Kamermans M, Spekreijse H. Effect of the tuberculosaticum ethambutol and stimulus intensity on chromatic
discrimination in man. *Vision Res.* 1999;39(17):2955–62.

23. Van Dijk B, Spekreijse H. Ethambutol changes the color coding in the carp retinal ganglion cells reversibly. *Invest Ophthalmol Vis Sci.* 1983;24(1):128–33.

24. Kohler K, Zrenner E, Weiler R. Ethambutol alters spine type synaptic connections and induces morphologic alterations in the cone pedicles of the fish retina. *Invest Ophthalmol Vis Sci.* 1995;36(6):1046–55.

25. Polak BC, Leys M, Van Lith G. Blue-yellow color-vision changes as early symptoms of ethambutol culotoxicity. *Ophthalmologica.* 1985;191(4):223–6.

26. Kaimbo WK, Bifuko ZA, Longo MB, Dralands L, Missotten L. Color vision in 42 Congolese patients with tuberculosis receiving ethambutol treatment. *Bull Soc Belge Ophtalmol.* 2002;284:57–61.

27. Kho RC, Al-Obailan M, Arnold AC. Bitemporal visual field defects in ethambutol-induced optic neuropathy. *J Neuro-ophthalmol.* 2011;31(2):121–6.

28. Garg P, Garg R, Prasad R, Mishra AK. A prospective study of ocular toxicity in patients receiving ethambutol as a part of directly observed treatment strategy therapy. *Lung India.* 2015;32(1):16–9.

**Author biography**

**Poorva Shrivastava,** Senior Resident

**Sheetal Morskole,** Junior Resident

**Lalit Shrivastava,** Consultant Ophthalmologist

---

**Cite this article:** Shrivastava P, Morskole S, Shrivastava L. Field changes on automated Humphrey’s field analyzer in tuberculosis following ethambutol therapy. *Indian J Clin Exp Ophthalmol* 2021;7(4):717–722.